Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity

Part of paid clinical trials in Los Angeles, California.

Sponsor
University of California, Los Angeles
Study ID
NCT06617312
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Smoking Cessation
  • Tobacco Use Disorder

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Cytisinicline — DRUG
    Targets α4β2 nicotinic acetylcholine receptors
  • Placebo Oral Capsule — DRUG
    Matched to active drug, cytisinicline

Study Details

This study will randomize 64 non-treatment seeking individuals who smoke cigarettes daily in a double-blind, placebo-controlled laboratory study testing the effects of cytisinicline on the neural substrates of cigarette cue reactivity.

Key Dates

Start date
Dec 5, 2024
Status verified
Nov 2025
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
64 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cytisinicline
    3mg cytisinicline oral capsule 3 times daily for 2-to-3 weeks
  • Placebo Comparator: Placebo
    matched to experimental drug

Primary Outcome Measure

Blood-oxygen-level-dependent (BOLD) activation to cigarette cues during fMRI task [ Time Frame: From enrollment to end of treatment at 2-to-3 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California Los AngelesLos AngelesCalifornia90049
Dylan E Kirsch, PhD
[email protected]
310-206-6756

Find similar trials in Los Angeles, CA

By research site
University of California Los Angeles· Los Angeles, CA

Related Studies